Cardiotoxicity Market: Industry Analysis, Epidemiology, Pipeline Therapies, Treatment and Companies by DelveInsight| Moleculin Biotech, Monopar Therapeutics and Others.
Cardiotoxicity is a condition when there is damage to the heart muscle. It may be caused by chemotherapy drugs or medications concerning other diseases. As a result of cardiotoxicity, the heart becomes weaker and is unable to pump blood throughout the body.
DelveInsight's "Cardiotoxicity
Market Insights, Epidemiology, and Market Forecast-2030" report
delivers an in-depth understanding of the Cardiotoxicity, historical and
forecasted epidemiology as well as the Cardiotoxicity market trends in the
United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and
Japan.
Some Key Highlights
from the Cardiotoxicity
Market Report:
- Cardiotoxicity
was found in 39.6% of anthracycline-treated patients in a recent study
(Sendon et al., 2020).
- Cardiotoxicity
also seen in patients who were taking anti-HER2 (43.5%), anthracycline and
anti-HER2 (45.7%), TKI (50%), left breast radiotherapy (44.8%), and
mediastinal radiotherapy (29.1%). (Sendon et al., 2020).
- Around
one-third of cancer patients who receive chemotherapy drugs including
trastuzumab (Herceptin) and anthracyclines have heart cell damage
(University of Michigan, n.d.).
- Cardiotoxicity
pipeline therapies include Annamycin (Moleculin Biotech), Camsirubicin
(Monopar Therapeutics), and others.
- Moleculin
Biotech, Monopar Therapeutics, among others are the major pharmaceutical
companies in the Cardiotoxicity market.
View Report: https://www.delveinsight.com/report-store/cardiotoxicity-market
To gain more insights
request sample @ https://www.delveinsight.com/sample-request/cardiotoxicity-market
Cardiotoxicity
Epidemiology Segmentation
- Various
Cancer Total Incident Cases
- Various
Cancer Total Number of Patients taking Chemotherapy
- Cardiotoxicity
Total Number of Patients taking Specific Chemotherapy Agents
- Cardiotoxicity
Total Number of Patients
Cardiotoxicity
Treatment Landscape
- Dexrazoxan
- ACE
inhibitors
- Beta-blockers
- Diuretics
- Digoxin
- Vasodilators
View Report: https://www.delveinsight.com/report-store/cardiotoxicity-market
To gain more insights
request sample @ https://www.delveinsight.com/sample-request/cardiotoxicity-market
Some of the Cardiotoxicity
Companies:
- Moleculin
Biotech
- Monopar
Therapeutics
- And
Many Others
Cardiotoxicity
Pipeline Therapies:
- Annamycin
- Camsirubicin
- And
Many Others
View Report: https://www.delveinsight.com/report-store/cardiotoxicity-market
To gain more insights
request sample @ https://www.delveinsight.com/sample-request/cardiotoxicity-market
Table of Contents
1. |
Report Introduction |
2. |
Executive Summary of Cardiotoxicity |
3. |
Cardiotoxicity Market Overview at a Glance |
4. |
Disease Background and Overview: Cardiotoxicity |
5. |
Case Reports of Cardiotoxicity |
6. |
Cardiotoxicity Patient Journey |
7. |
Cardiotoxicity Epidemiology and Patient Population |
8. |
Epidemiology of Cardiotoxicity by Countries (2018–2030) |
9. |
Cardiotoxicity Treatments and Medical Practices |
10. |
Cardiotoxicity Marketed Therapies |
11. |
Cardiotoxicity Emerging Therapies |
12. |
Cardiotoxicity Market Size |
13. |
7MM: Country-wise Market Analysis |
14. |
Cardiotoxicity Market Drivers |
15. |
Cardiotoxicity Market Barriers |
16. |
SWOT Analysis |
17. |
KOL Views |
18. |
Reimbursement and market access |
19. |
Report Methodology |
20. |
DelveInsight Capabilities |
21. |
Disclaimer |
22. |
About DelveInsight |
About DelveInsight
DelveInsight is a leading Business Consultant and Market
Research firm focused exclusively on life sciences. It supports Pharma
companies by providing end to end comprehensive solutions to improve their
performance.
Cardiotoxicity market,Cardiotoxicity market trends,Cardiotoxicity market forecast,Cardiotoxicity market share,Cardiotoxicity pipeline,Cardiotoxicity treatment algorithm,Cardiotoxicity drugs,Cardiotoxicity market size,Cardiotoxicity CAGR,Cardiotoxicity epidemiology
Comments
Post a Comment